Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
15 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-06-13
Study Completion Date
2017-04-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
\- Small differences in genes may alter responses to drugs. One gene that has different forms is the mu opioid receptor gene. People with one form of this gene are more sensitive to alcohol. People with a different form are sometimes more sensitive to pain. Morphine and other prescription pain pills produce pain relief by acting at the mu opioid receptor. Researchers want to see the effect of morphine on brain reward and subjective effects. Morphine is a strong but short-acting pain medication that is sometimes used for anesthesia during surgery.
Objectives:
\- To compare the effect of morphine on brain measures of dopamine release using imaging.
Eligibility:
\- Individuals between 21 and 55 years of age who have previously taken pain pills prescribed to treat pain from a medical or dental procedure.
Design:
* This study has a screening phase and a study phase. The screening phase involves one or two visits of 5 to 6 hours. The study phase consists of 4 study visits. Each study visit will take about 8 hours.
* Participants will be screened with a medical and psychiatric history and physical exam. They will be asked about drinking and drug-taking history, and any family history of alcoholism or drug abuse. Blood, urine, and breath samples will be collected.
* During the first study visit, an MRI scan may be performed, questionnaires completed, and a blood sample collected for genetic testing.
* During study visit 2, participants will test their pain sensitivity by placing one hand in cold water. Pupil diameter will be measured after the sensitivity test. After a blood sample is taken, participants will receive the morphine or a salt solution. The sensitivity test and pupil diameter test will be repeated. Final blood samples will be collected. A brief physical exam will also be performed.
* During study visits 3 and 4, participants will receive morphine or a salt solution during a PET scan. Questionnaires to assess subjective effects will be administered. Final blood samples will be collected. A brief physical exam will also be performed.
* Participants will stay in the clinic until the effects of the drug have worn off after study visits 2, 3, and 4.
* About 1 week after the study session, participants will have a follow-up phone call.
\- Small differences in genes may alter responses to drugs. One gene that has different forms is the mu opioid receptor gene. People with one form of this gene are more sensitive to alcohol. People with a different form are sometimes more sensitive to pain. Morphine and other prescription pain pills produce pain relief by acting at the mu opioid receptor. Researchers want to see the effect of morphine on brain reward and subjective effects. Morphine is a strong but short-acting pain medication that is sometimes used for anesthesia during surgery.
Objectives:
\- To compare the effect of morphine on brain measures of dopamine release using imaging.
Eligibility:
\- Individuals between 21 and 55 years of age who have previously taken pain pills prescribed to treat pain from a medical or dental procedure.
Design:
* This study has a screening phase and a study phase. The screening phase involves one or two visits of 5 to 6 hours. The study phase consists of 4 study visits. Each study visit will take about 8 hours.
* Participants will be screened with a medical and psychiatric history and physical exam. They will be asked about drinking and drug-taking history, and any family history of alcoholism or drug abuse. Blood, urine, and breath samples will be collected.
* During the first study visit, an MRI scan may be performed, questionnaires completed, and a blood sample collected for genetic testing.
* During study visit 2, participants will test their pain sensitivity by placing one hand in cold water. Pupil diameter will be measured after the sensitivity test. After a blood sample is taken, participants will receive the morphine or a salt solution. The sensitivity test and pupil diameter test will be repeated. Final blood samples will be collected. A brief physical exam will also be performed.
* During study visits 3 and 4, participants will receive morphine or a salt solution during a PET scan. Questionnaires to assess subjective effects will be administered. Final blood samples will be collected. A brief physical exam will also be performed.
* Participants will stay in the clinic until the effects of the drug have worn off after study visits 2, 3, and 4.
* About 1 week after the study session, participants will have a follow-up phone call.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans
NCT02360371
Opioid Sensitivity
Individual Difference
Abuse Opioids
COMPLETED
PHASE2
Effects of Nicotine on Brain Opioid Receptors
NCT01040338
Nicotine Dependence
TERMINATED
Determining Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction
NCT01562353
Usage of Prescription Opioids
UNKNOWN
Pharmacogenetics of Naltrexone for Stimulant Abuse
NCT03226223
Substance Use Disorders
Methamphetamine Abuse
COMPLETED
PHASE2
Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts
NCT01668706
Heroin Dependence
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives
Mesolimbic dopamine (DA) release is a key signal for drug reward, and endogenous opioids are thought to exert their effects in part by modulating the activity of this system. A functional ยต-opioid receptor (OPRM1) A118G single nucleotide polymorphism (SNP) has been associated with increased risk for heroin addiction in some studies. This polymorphism has been shown to confer differential pain sensitivity and to alter the release of DA following an alcohol challenge. The objective of this study is to examine the role of the A118G OPRM1 polymorphism for responses to a challenge of an opiate (morphine) with regard to psycho-physiological variables measured in the laboratory and for brain dopamine release measured by \[11C\]raclopride PET.
Study Population
Healthy male participants who have had experience with oral prescription analgesics (e.g., Oxycontin, Vicodin, Percocet, oxycodone) will be recruited for the study. These volunteers will be screened to obtain samples of two groups of subjects: 1) persons homozygous for the major 118A allele (118AA genotype); 2) persons carrying one or two copies of the variant 118G allele (118AG or 118GG genotype, hereafter called 118GX). We will recruit up to 120 participants to obtain 40 completers per genotype for the study.
Design
We will compare the response of these groups to a challenge with morphine given intravenously. Participants will receive a standardized IV challenge of morphine (10.0 mg/70 kg over 1 minute; morphine concentration 2 mg/ml). Pre and post injection measures will be made in two areas: 1) subjective response as measured by standardized questionnaires, and 2) measures of physiological response, including pupil response to light, respiratory rate, oxygen saturation and a pain rating from putting a hand in cold water and blood chemistries. In addition, during this visit, participants will wear the AutoSense mobile physiological monitor; parameters measured by AutoSense include respiration rate, heart rate, heart-rate variability, skin conductance, and activity level. The injection will be repeated in all participants in the PET scanner, once with morphine and once with normal saline. Dopamine release will be assessed by determining the difference between the binding potential for \[11C\]raclopride, a positron emitter labeled ligand which binds preferentially to D2 receptors during saline administration and its binding potential during morphine administration.
Outcome measures
We hypothesize that 118GX subjects will have significantly different subjective response to the challenge than 118AA subjects as observed in participants receiving alcohol in a similar study (Ramchandani et al. 2011). However, the genotype effect on the response may be opposite from the effect of genotype on the alcohol response. We also hypothesize that the PET studies with \[11C\]raclopride will show that 118GX subjects have less dopamine release during morphine administration than 118 AA subjects.
Mesolimbic dopamine (DA) release is a key signal for drug reward, and endogenous opioids are thought to exert their effects in part by modulating the activity of this system. A functional ยต-opioid receptor (OPRM1) A118G single nucleotide polymorphism (SNP) has been associated with increased risk for heroin addiction in some studies. This polymorphism has been shown to confer differential pain sensitivity and to alter the release of DA following an alcohol challenge. The objective of this study is to examine the role of the A118G OPRM1 polymorphism for responses to a challenge of an opiate (morphine) with regard to psycho-physiological variables measured in the laboratory and for brain dopamine release measured by \[11C\]raclopride PET.
Study Population
Healthy male participants who have had experience with oral prescription analgesics (e.g., Oxycontin, Vicodin, Percocet, oxycodone) will be recruited for the study. These volunteers will be screened to obtain samples of two groups of subjects: 1) persons homozygous for the major 118A allele (118AA genotype); 2) persons carrying one or two copies of the variant 118G allele (118AG or 118GG genotype, hereafter called 118GX). We will recruit up to 120 participants to obtain 40 completers per genotype for the study.
Design
We will compare the response of these groups to a challenge with morphine given intravenously. Participants will receive a standardized IV challenge of morphine (10.0 mg/70 kg over 1 minute; morphine concentration 2 mg/ml). Pre and post injection measures will be made in two areas: 1) subjective response as measured by standardized questionnaires, and 2) measures of physiological response, including pupil response to light, respiratory rate, oxygen saturation and a pain rating from putting a hand in cold water and blood chemistries. In addition, during this visit, participants will wear the AutoSense mobile physiological monitor; parameters measured by AutoSense include respiration rate, heart rate, heart-rate variability, skin conductance, and activity level. The injection will be repeated in all participants in the PET scanner, once with morphine and once with normal saline. Dopamine release will be assessed by determining the difference between the binding potential for \[11C\]raclopride, a positron emitter labeled ligand which binds preferentially to D2 receptors during saline administration and its binding potential during morphine administration.
Outcome measures
We hypothesize that 118GX subjects will have significantly different subjective response to the challenge than 118AA subjects as observed in participants receiving alcohol in a similar study (Ramchandani et al. 2011). However, the genotype effect on the response may be opposite from the effect of genotype on the alcohol response. We also hypothesize that the PET studies with \[11C\]raclopride will show that 118GX subjects have less dopamine release during morphine administration than 118 AA subjects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Polymorphism-Genetic
Pain
Addiction
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Crossover study - participants receive active and placebo treatments in randomized order.
Primary Study Purpose
OTHER
Blinding Strategy
DOUBLE
Participants
Investigators
Bliniding
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Morphine
Morphine injection 10 mg/70kg
Group Type
EXPERIMENTAL
Morphine
Intervention Type
DRUG
Placebo
Saline injection
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Morphine
Intervention Type
DRUG
Placebo
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male participants between 21-55 years of age.
2. Good health as determined by medical history, physical exam, EKG and lab tests.
3. Current non-smokers or light smokers or e-cigarette users (\<20 cig/week) who can easily abstain from smoking or using e-cigarettes for 1-2 days/week.
4. Current non-drinkers or social drinkers who do not meet past or current DSM IV criteria for alcohol abuse or alcohol dependence.
5. An equal number of final participants will be of OPRM1 118 A/A vs. 118A/G or 118G/G genotype. This means that after the first group (n40) is complete then only participants with the required genotype for the other group will be included.
6. Prior opiate use, at least one experience with one of the opiates listed in Appendix 1 of the protocol.
7. Comprehension/fluency with English Language.
2. Good health as determined by medical history, physical exam, EKG and lab tests.
3. Current non-smokers or light smokers or e-cigarette users (\<20 cig/week) who can easily abstain from smoking or using e-cigarettes for 1-2 days/week.
4. Current non-drinkers or social drinkers who do not meet past or current DSM IV criteria for alcohol abuse or alcohol dependence.
5. An equal number of final participants will be of OPRM1 118 A/A vs. 118A/G or 118G/G genotype. This means that after the first group (n40) is complete then only participants with the required genotype for the other group will be included.
6. Prior opiate use, at least one experience with one of the opiates listed in Appendix 1 of the protocol.
7. Comprehension/fluency with English Language.
Exclusion Criteria
1. Current or prior history of any significant disease, including cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders, or a positive hepatitis or HIV test at screening, disorders that could make administration of an opiate more risky (e.g., asthma, COPD, sleep apnea, or other breathing disorders; liver or kidney disease; thyroid disorder; trouble swallowing, or a blockage in the digestive tract (stomach or intestines); neurologic disorders (e.g., a history of head injury or brain tumor, epilepsy or other seizure disorder, CVA, migraine in treatment, etc.); low blood pressure; hypertension; neuromuscular disorder; gallbladder disease; Addison's disease or other adrenal gland disorders; enlarged prostate, urination problems)
2. Current Axis-I psychiatric illness as determined by the Structured Clinical Interview for DSM IV disorders (SCID).
3. Current or prior history of any alcohol or drug dependence as determined by the Structured Clinical Interview for DSM IV disorders (SCID).
4. Positive result on urine screen for illicit drugs.
5. Medication Use:
1. Current chronic prescription or over the counter medications or use of prescription or OTC medications known to interact with dopamine receptors within 2 weeks of the study
2. Drugs known to inhibit or induce enzymes that metabolize opiates should not be used for 4 weeks prior to the study. These include chlorzoxazone, isoniazid, metronidazole and disulfiram.
3. Cough-and-cold preparations that contain anti-histamines or opiate pain medicines will be withheld for at least 72 hours prior to each study session.
4. Drugs that may interfere with the BOLD MRI signal within 2 weeks of the study. These include, but may not be limited to: muscle relaxants or respiratory, cardiovascular or anticonvulsant medications
6. Morbid obesity (BMI \>40 kg/m2)
7. Previous negative effects of opioid administration
8. Presence of certain implanted devices (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts), body morphology, or claustrophobia. Justification: Implanted devices may increase the risk of MRI scanning and/or adversely affect the quality of the data; body morphology may prevent optimal positioning in the scanner and thus affect the quality of the data; participants with claustrophobia may find the MRI scan too unpleasant and may exhibit excess movement that will adversely affect the quality of the data. Assessment tool(s): Prospective participants will fill out an MRI screening questionnaire and undergo an interview with an MR technologist. Questions concerning suitability for scanning will be referred to the Medical Advisory Investigator. Prospective participants will be questioned about symptoms of claustrophobia and placed in the mock scanner during their first visit to assess for possible difficulty tolerating the confinement of the scanner and for ability to fit into the scanner.
9. Conditions restricting participant's ability to lie flat for up to two hours (such as coagulopathies, superficial or deep vein thrombosis, or musculoskeletal abnormalities). Justification: PET scanning sessions require participants to lie flat on their backs and remain perfectly still for approximately two hours. Therefore, conditions that would make that difficult (e.g., chronic back pain, significant scoliosis) or dangerous (e.g., familial hypercoagulability syndrome, history of thrombosis) will be exclusionary. Assessment tool(s): History and physical examination by a qualified IRP clinician, supplemented with a trial of lying in the mock scanner to assess comfort.
10. Head trauma leading to loss of consciousness for more than 5 min or hospitalization
11. Exposure to ionizing radiation from research studies that, in combination with the study tracer, would result in cumulative exposure of \>5 rem within the previous 12 month period
12. Self-reported and/or observed signs, symptoms, or diagnosis of Raynaud's or Buerger's disease (e.g., pain in hands or feet at times of rest, during/following cold exposure or stress, any significant color changes in hands or toes). Additionally, medical staff will be present to watch for these symptoms during the actual cold pressor test.
2. Current Axis-I psychiatric illness as determined by the Structured Clinical Interview for DSM IV disorders (SCID).
3. Current or prior history of any alcohol or drug dependence as determined by the Structured Clinical Interview for DSM IV disorders (SCID).
4. Positive result on urine screen for illicit drugs.
5. Medication Use:
1. Current chronic prescription or over the counter medications or use of prescription or OTC medications known to interact with dopamine receptors within 2 weeks of the study
2. Drugs known to inhibit or induce enzymes that metabolize opiates should not be used for 4 weeks prior to the study. These include chlorzoxazone, isoniazid, metronidazole and disulfiram.
3. Cough-and-cold preparations that contain anti-histamines or opiate pain medicines will be withheld for at least 72 hours prior to each study session.
4. Drugs that may interfere with the BOLD MRI signal within 2 weeks of the study. These include, but may not be limited to: muscle relaxants or respiratory, cardiovascular or anticonvulsant medications
6. Morbid obesity (BMI \>40 kg/m2)
7. Previous negative effects of opioid administration
8. Presence of certain implanted devices (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts), body morphology, or claustrophobia. Justification: Implanted devices may increase the risk of MRI scanning and/or adversely affect the quality of the data; body morphology may prevent optimal positioning in the scanner and thus affect the quality of the data; participants with claustrophobia may find the MRI scan too unpleasant and may exhibit excess movement that will adversely affect the quality of the data. Assessment tool(s): Prospective participants will fill out an MRI screening questionnaire and undergo an interview with an MR technologist. Questions concerning suitability for scanning will be referred to the Medical Advisory Investigator. Prospective participants will be questioned about symptoms of claustrophobia and placed in the mock scanner during their first visit to assess for possible difficulty tolerating the confinement of the scanner and for ability to fit into the scanner.
9. Conditions restricting participant's ability to lie flat for up to two hours (such as coagulopathies, superficial or deep vein thrombosis, or musculoskeletal abnormalities). Justification: PET scanning sessions require participants to lie flat on their backs and remain perfectly still for approximately two hours. Therefore, conditions that would make that difficult (e.g., chronic back pain, significant scoliosis) or dangerous (e.g., familial hypercoagulability syndrome, history of thrombosis) will be exclusionary. Assessment tool(s): History and physical examination by a qualified IRP clinician, supplemented with a trial of lying in the mock scanner to assess comfort.
10. Head trauma leading to loss of consciousness for more than 5 min or hospitalization
11. Exposure to ionizing radiation from research studies that, in combination with the study tracer, would result in cumulative exposure of \>5 rem within the previous 12 month period
12. Self-reported and/or observed signs, symptoms, or diagnosis of Raynaud's or Buerger's disease (e.g., pain in hands or feet at times of rest, during/following cold exposure or stress, any significant color changes in hands or toes). Additionally, medical staff will be present to watch for these symptoms during the actual cold pressor test.
Minimum Eligible Age
21 Years
Maximum Eligible Age
55 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Sponsor Role
collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vijay A Ramchandani, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Barr CS, Schwandt M, Lindell SG, Chen SA, Goldman D, Suomi SJ, Higley JD, Heilig M. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry. 2007 Mar;64(3):369-76. doi: 10.1001/archpsyc.64.3.369.
Reference Type
BACKGROUND
Bart G, Heilig M, LaForge KS, Pollak L, Leal SM, Ott J, Kreek MJ. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry. 2004 Jun;9(6):547-9. doi: 10.1038/sj.mp.4001504. No abstract available.
Reference Type
BACKGROUND
Callaghan RC, Cunningham JK, Verdichevski M, Sykes J, Jaffer SR, Kish SJ. All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study. Drug Alcohol Depend. 2012 Oct 1;125(3):290-4. doi: 10.1016/j.drugalcdep.2012.03.004. Epub 2012 Apr 13.
Reference Type
BACKGROUND
Spagnolo PA, Kimes A, Schwandt ML, Shokri-Kojori E, Thada S, Phillips KA, Diazgranados N, Preston KL, Herscovitch P, Tomasi D, Ramchandani VA, Heilig M. Striatal Dopamine Release in Response to Morphine: A [11C]Raclopride Positron Emission Tomography Study in Healthy Men. Biol Psychiatry. 2019 Sep 1;86(5):356-364. doi: 10.1016/j.biopsych.2019.03.965. Epub 2019 Mar 15.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-AA-0061.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-AA-0061
Identifier Type: -
Identifier Source: secondary_id
130061
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Pharmacogenetic Response to Naltrexone For Alcohol Dependence
NCT00831272
COMPLETED
PHASE4
Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure
NCT05463367
ACTIVE_NOT_RECRUITING
PHASE2
Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms
NCT01502644
COMPLETED
PHASE4
Study of Naltrexone for Methamphetamine Addiction
NCT00984360
COMPLETED
PHASE2
Understanding Treatment Response With Naltrexone Among White Alcoholics
NCT00817089
COMPLETED
PHASE4
A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Opioids for the Treatment of Chronic Pain
NCT02751762
COMPLETED
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
NCT05919797
RECRUITING
PHASE4
Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
NCT02662153
COMPLETED
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
NCT02224508
COMPLETED
Aprepitant Effects on Oxycodone Response
NCT00999544
COMPLETED
NA
Neuroimaging of Opioid Phase (OPAL)
NCT05905419
RECRUITING
NA
The Effects of Opioid Taper on Opioid-Induced Hyperalgesia
NCT03063905
TERMINATED
Health Outcomes From Opioid Therapy for Chronic Pain
NCT00495404
COMPLETED
NA
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)
NCT04445792
COMPLETED
NA
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
NCT05988710
RECRUITING
PHASE4
Developing Brain Stimulation as a Treatment for Chronic Pain in Opiate Dependent
NCT03681769
COMPLETED
EARLY_PHASE1
A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
NCT03389750
COMPLETED
PHASE2
Sensory and Opioid Mechanisms of Affective Touch
NCT03096353
COMPLETED
EARLY_PHASE1
Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
NCT01822132
COMPLETED
NA
Sensory Outcomes in Active Substance Users
NCT06639438
RECRUITING
NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study
NCT02692157
WITHDRAWN
PHASE1/PHASE2
Pain and Opioid Management in Older Adults
NCT05037682
RECRUITING
NA
Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder
NCT04495673
TERMINATED
NA
Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers
NCT02250664
COMPLETED
PHASE1/PHASE2
Buprenorphine Pharmacology Related to Addiction Treatment - 18
NCT00000236
COMPLETED
PHASE2